Zogenix Inc.
This article was originally published in Start Up
Executive Summary
When GlaxoSmithKline's patent on sumatriptan expires in 2009 (if not sooner), a substantial portion of the $2.5 billion triptan market for treatment of acute migraine will open up to competitors. Launched just this past August, Zogenix plans to have its version of sumatriptan succinate delivered via a pre-filled, needle-free, single-use, and disposable injection system ready for the market.